Technology evaluation: WX-G250, Wilex/Ludwig Institute for Cancer Research.
Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). The antibody is currently undergoing phase II clinical trials for RCC and preclinical development for biliary cancer.
Kennett
Roger H
RH
Department of Biology, Wheaton College, Wheaton, IL 60187, USA. Roger.H.Kennett@wheaton.edu
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000628:therapy; D017322:Clinical Trials, Phase II as Topic; D005706:Gallbladder Neoplasms / Q000628:therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; C106533:G250 monoclonal antibody; D007457:Iodine Radioisotopes; D011993:Recombinant Fusion Proteins